PRO MEDICUS LIMITED — Annual Report 2015

Aug 20, 2015

Appendix 4E Preliminary Final Report

Rule 4.2A

Appendix 4E Preliminary Final Report

1. Company details

Name of entity

. Company details ame of entity	. Company details ame of entity
Pro Medicus Limited
ABN or equivalent company reference Financial year ended (‘current period’) 25 006 194 752 30 June 2015 . Results for announcement to the market
					30 June 2014
ASX Listing Rules **Ref **				2015 A$’000		2014 A$’000		% change
2.1	Revenue from continuing operations			17,577		14,447		21.7%
2.2 2.3	Profit/(Loss) from ordinary activities after tax attributable to members			3,217		1,509		113.2%
	Net Profit/(Loss) for the period attributable to members			3,217 Up 113.2%
	% change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.
2.4	Dividends (distributions)			Amount per security			Unfranked amount per security
	Unfranked dividend amount per security Final Dividend Interim dividend			1.0 cents 1.0 cents			1.0 cents 1.0 cents
2.5	Record date for Final dividends			11 September 2015
	Payment date for Final dividends			2 October 2015

Appendix 4E Page 1

Appendix 4E Preliminary Final Report

	2.6	Australia The Group’s Australian employees undertake research and development of Pro Medicus products (RIS) as well as sales and service/support functions. The Group’s Australian revenue was 1.9% above last year’ as a result of new sales of both the Visage PACS and Visage RIS products with many sales being for the combined product offering. Promedicus.net, the company’s e-health offering, continued to hold its strong market position despite increasing competition. North America The growing North American team fulfil sales, marketing and professional services roles. Revenue from North America increased by 67.2% compared to the previous year. This was largely attributable to new sales and an increase in transaction based revenue from sales of Visage technology as more contracts came on stream. Europe The Group’s employees in its Berlin office undertake research and development of Visage Imaging products worldwide as well as sales, marketing and service/support functions for the Group's European operations. Revenue from our European operations decreased by 16.3% from last year, due to lower OEM sales. Financials Reported profit after tax for the period was $3.22m an increase of $1.71m (113.2%) from the previous year. Full year revenue of the Group from continuing operations, increased from $14.45m to $17.58m, an increase of 21.7%. The key driver of the profit increase was the significant improvement in the performance of the North American operations supplemented by a modest increase in Australian sales. As the Group’s costs are relatively fixed, an increase in sales has a positive impact on profitability. Shareholder Returns The directors are confident that the holdings of reserve cash is sufficient to underpin the development and expansion needs of the company as the business looks to increase its penetration of existing markets.
	3.	Statement of Comprehensive Income Please refer to the Statement of Comprehensive Income in the attached Financial Statements.
	4.	Statement of Financial Position Pleasereferto the Statement of Financial Position inthe attachedFinancialStatements.
	5.	Statement of cash flows Pleasereferto the Statement ofcash flowsinthe attachedFinancialStatements.

Appendix 4E Page 2

Appendix 4E Preliminary Final Report

		Appendix 4E Preliminary Final Report
	6.	Details of Dividends 2015 $’000 2014 $’000 Final Dividend An unfranked Final Dividend of 1.0 cents (2014: 1.0 cents) per share will be paid on 2 October 2015. 1,002 1,002 Current Year Interim An unfranked Interim Dividend of 1.0 cents (2014: 1.0 cents) per share was paid on 20 March 2015. 1,002 1.002 No foreign sourced dividend or distribution is included in either the interim or final dividends.
	7.	Dividend or Distribution reinvestment plans There are no dividend or distribution reinvestment plans in operation.
	8.	Statement of Retained Earnings Please refer to Statement of Changes in Equity in the attached Financial Statements.
	9.	Net Tangible Assets per security 2015 2014 Net Tangible Assets per security $0.13 $0.13
	10.	Details of entities over which control has been gained or lost during the period There are no entities over which control has been gained or lost during the period
	11.	Associates and joint venture entities There are no associates or joint venture entities
	12.	Other significant information needed by an investor to make an informed assessment of the entity’s financial performance and financial position. Please refer to section 2.6
	13.	Foreign Entity accounting standards Australian Accounting Standards &International Financial Reporting Standards

Appendix 4E Page 3

Appendix 4E Preliminary Final Report

14. Commentary on results for the period. The earnings per security and the nature of any dilution aspects . Please refer to Note 8 of the attached Financial Statements.

Returns to shareholders including distributions and buy backs. Please refer to Note 9 of the attached Financial Statements.

Significant features of operating performance . Please refer to section 2.6.

The results of segments that are significant to an understanding of the business. Please refer to Note 5 of the attached Financial Statements.

Discussion of trends in performance. Please refer to section 2.6.

15. Audit Statement

This report is based on accounts to which one of the following applies. (Tick one)

 The +accounts have been  The[+] accounts have been subject to audited. review. [The ] +accounts are in the [The ][+][accounts have ] [not][yet][been ] process of being audited. audited or reviewed.

Sign here:

Date: 21 August 2015

==> picture [209 x 68] intentionally omitted <==

Print name: Sam Hupert Chief Executive Officer

Appendix 4E Page 4